GnRH Antagonist Injections and Fresh Embryo Transfer Outcomes
The number of GnRH antagonist injections does not appear to directly impact fresh embryo transfer success rates based on available evidence, though the specific protocol modifications and timing of antagonist use may influence outcomes.
Evidence from IUI Guidelines (Limited Applicability to IVF/ET)
The available guideline evidence primarily addresses intrauterine insemination (IUI) rather than fresh embryo transfer specifically. The 2018 Human Reproduction Update guidelines explicitly recommend against adding GnRH agonists or antagonists to gonadotropin protocols in IUI-OS, as there is no increase in pregnancy rate despite increased multiple pregnancy rates and costs 1. However, this recommendation applies to IUI cycles, not IVF with fresh embryo transfer, limiting its direct applicability to your question.
Research Evidence on Antagonist Protocols in Fresh IVF Cycles
Protocol Modifications Show Promise
The most recent and highest quality evidence suggests that protocol modifications—specifically early cessation of GnRH antagonist on the day of hCG administration combined with a gonadotropin step-down approach—significantly improves live birth rates in fresh single embryo transfer cycles 2. This 2024 randomized controlled trial demonstrated:
- Live birth rates of 38.1% in the modified antagonist group versus 27.5% in conventional antagonist group (P = 0.008) 2
- The modified protocol achieved significantly higher implantation rates and clinical pregnancy rates 2
- No differences in OHSS incidence between groups 2
Number of Injections: Historical Context
Earlier studies examined different dosing frequencies but focused on preventing LH surge rather than optimizing pregnancy outcomes:
- A 1998 study compared single-dose administration of 3 mg versus 2 mg Cetrorelix, finding both successfully prevented LH surges for at least 3 days, though the 3 mg dose was deemed safer 3
- High doses of antagonist (1-2 mg daily) were associated with low implantation rates in fresh cycles, though frozen embryo outcomes from these cycles remained unaffected 4
Comparative Outcomes: Antagonist vs. Agonist Protocols
Multiple studies have compared antagonist protocols to agonist protocols, with mixed findings:
- A 2019 retrospective study found GnRH antagonist protocols were associated with significantly lower clinical pregnancy rates (P<0.001) and live birth rates (P<0.001) compared to agonist protocols, though OHSS rates were lower with antagonists (P=0.039) 5
- A 2009 case-control study showed antagonist use resulted in higher rates of cytoplasmic abnormalities in oocytes (62.1% vs. 49.9%, P<0.01) but higher cell numbers in day-2 preembryos 6
Clinical Implications
The critical factor appears to be the protocol design rather than simply the number of antagonist injections administered. The evidence suggests:
- Early cessation of antagonist (stopping on hCG day rather than continuing through trigger) combined with gonadotropin dose reduction improves fresh transfer outcomes 2
- Traditional multiple-dose antagonist protocols may result in suboptimal endometrial receptivity, which is a key factor contributing to poorer fresh cycle outcomes 2
- The timing and duration of antagonist exposure, rather than the absolute number of injections, likely influences fresh embryo transfer success 2, 3
Important Caveats
- Most available evidence focuses on protocol comparisons (antagonist vs. agonist) rather than specifically examining the impact of varying numbers of antagonist injections within the same protocol type 6, 5
- The 2024 study demonstrating improved outcomes with modified antagonist protocols only included women under 40 years with good prognosis, limiting generalizability to older patients or those with diminished ovarian reserve 2
- The ESHRE 2024 embryo transfer guidelines do not specifically address antagonist injection frequency as a factor in transfer decision-making 1